Brief introduction of Jilin Aodong Pharmaceutical Group Yanji Co., Ltd.

The company has 640 employees and more than 200 researchers. It can produce 7 dosage forms such as large-capacity injection, freeze-dried powder injection, small-capacity injection, capsule, granule, oral liquid and tablet, and 120 kinds of Chinese and western medicines, bulk drugs and biochemical drugs. It has basically formed a series of anti-tumor and improving human immunity, mainly including ribonucleic acid II (BP) for injection, thymosin for injection, transfer factor for injection, Qi Zhen Fuzheng Granule and Guyuan Granule. A series of hepatobiliary treatments, mainly "compound Xiongdan hepatitis B capsule" and "hepatocyte growth-promoting factor for injection"; A series of cardiovascular and cerebrovascular drugs, mainly including propyl gallate for injection, zintinol nicotinate for injection and cerebroprotein hydrolysate injection; Nourishing drugs mainly include Guiqishen Oral Liquid, Wujiarongxue Oral Liquid and Bushen Shen Qiang Capsule. And antiviral, broad-spectrum anti-inflammatory and bactericidal products; It is a high-tech enterprise with complete dosage forms, many varieties, good market adaptability and strong comprehensive economic strength.

Relying on Changbai Mountain's rich medicinal resources and the advantages of the group, the company develops ethnic medicine products, pursues the business philosophy of "people's health is Aodong's responsibility", adheres to the principle of "talent-oriented, science and technology as the guide, strict quality requirements, good after-sales service and reliable reputation", constantly implements scientific and technological innovation, takes the road of modernization of traditional Chinese medicine and relies on the joint development of scientific research institutes. Develop a batch, reserve a batch and develop a batch. New drugs have been developed in nearly 20 countries, and some products have been rated as national key new products and won the innovation fund of the Ministry of Science and Technology, which has added stamina for the development of enterprises. Up to now, the company has achieved an output value of 7843 1 10,000 yuan, a profit of 4372 yuan, and a tax payment of 53.05 million yuan, achieving the strategic goal of leaping development, which was inspected and fully affirmed by Chairman Wu Bangguo.

The company is the designated manufacturer of Korean medicines for ethnic minority products. While producing traditional Chinese medicine, western medicine and biochemical medicine, it highlights national characteristics and becomes a medicine. According to the national policy of "prospering the border and enriching the people" and the requirements of industry certification, we invested 1 100 million yuan to implement the technical transformation of GMP relocation, and passed the national drug GMP certification at the end of 20001,which improved the company's production capacity, labor efficiency and self-development ability to a new level and achieved "high quality, high efficiency and first class". In accordance with the guiding ideology of "three benefits", we should take product development as the breakthrough, focus on marketing, and take performance appraisal as the regular work, comprehensively improve the management level of enterprises, find advantages in varieties, find a position in the market, realize sustained, rapid and healthy economic development, and repay shareholders and society with better economic benefits.